dc.creator | Tsoukalas N., Kostakis I.D., Giaginis C., Tolia M., Galanopoulos M., Kiakou M., Aravantinou-Fatorou E., Tsapakidis K., Baxevanos P., Litos I., Tzouda V., Tzovaras A., Kyrgias G., Tsiambas E., Theocharis S. | en |
dc.date.accessioned | 2023-01-31T10:19:19Z | |
dc.date.available | 2023-01-31T10:19:19Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 11070625 | |
dc.identifier.uri | http://hdl.handle.net/11615/80157 | |
dc.description.abstract | Purpose: Τo investigate the potential diagnostic and prognostic role of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) serum levels in non-small cell lung cancer (NSCLC). Methods: One hundred consecutive patients with newly diagnosed primary NSCLC were included in this study (88 men and 12 women). Blood was drawn before any kind of treatment and the collected serum was processed using chemiluminescence in order CEA and CA 19-9 levels to be measured. Results: No significant associations between CEA or CA 19-9 levels and any tested clinical and pathological parameter were detected. Moreover, CEA levels did not seem to affect survival. On the other hand, patients with high CA 19-9 values (≥37 IU/ml) (median survival: 8 months) had a shorter overall survival than patients with low CA 19-9 values (<37 IU/ml) (median survival: 13 months) (p=0.026). However, CA 19-9 levels did not remain an independent prognostic factor in the multivariate survival analysis (p=0.114). Conclusion: CEA and CA 19-9 serum levels do not seem to have any diagnostic role in NSCLC. With regard to their prognostic role, CEA values do not seem to affect the prognosis in NSCLC. However, high CA 19-9 values are associated with worse prognosis. © 2017 Zerbinis Publications. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Journal of B.U.ON. | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045627433&partnerID=40&md5=22825d0e081900b45286974095c77b69 | |
dc.subject | CA 19-9 antigen | en |
dc.subject | carcinoembryonic antigen | en |
dc.subject | CA 19-9 antigen | en |
dc.subject | carcinoembryonic antigen | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | blood level | en |
dc.subject | chemoluminescence | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | non small cell lung cancer | en |
dc.subject | overall survival | en |
dc.subject | Review | en |
dc.subject | survival analysis | en |
dc.subject | blood | en |
dc.subject | genetics | en |
dc.subject | lung tumor | en |
dc.subject | middle aged | en |
dc.subject | non small cell lung cancer | en |
dc.subject | pathology | en |
dc.subject | prognosis | en |
dc.subject | very elderly | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | CA-19-9 Antigen | en |
dc.subject | Carcinoembryonic Antigen | en |
dc.subject | Carcinoma, Non-Small-Cell Lung | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Lung Neoplasms | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Prognosis | en |
dc.subject | Zerbinis Publications | en |
dc.title | Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer | en |
dc.type | other | en |